IL4/IL13 receptor molecule for veterinary use
Provided are various embodiments relating to interleukin 13 receptor subunit alpha-1/interleukin 4 receptor subunit alpha (IL13R/IL4R) contiguous polypeptides derived from companion animal species and that bind to IL13 and/or IL4. Such contiguous polypeptides can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.
1. A polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31.
2. The polypeptide of claim 1 , comprising a post-expression modification.
3. The polypeptide of claim 2 , wherein the modification comprises glycosylation, sialyation, acetylation, and/or phosphorylation.
4. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.
5. The polypeptide of claim 4 , wherein the polypeptide binds to IL13 of a companion animal species with a dissociation constant (Kd) of less than 5×10 −6 M, as measured by biolayer interferometry.
6. The polypeptide of claim 4 , wherein the polypeptide binds to IL4 of a companion animal species with a dissociation constant (Kd) of less than 5×10 −6 M, as measured by biolayer interferometry.
7. The polypeptide of claim 4 , comprising a post-expression modification.
8. The polypeptide of claim 7 , wherein the modification comprises glycosylation, sialyation, acetylation, and/or phosphorylation.
9. The polypeptide of claim 1 , wherein the polypeptide comprises SEQ ID NO: 15.
10. The polypeptide of claim 9 , wherein the polypeptide binds to IL13 of a companion animal species with a dissociation constant (Kd) of less than 5×10 −6 M, as measured by biolayer interferometry.
11. The polypeptide of claim 9 , wherein the polypeptide binds to IL4 of a companion animal species with a dissociation constant (Kd) of less than 5×10 −6 M, as measured by biolayer interferometry.
12. The polypeptide of claim 9 , comprising a post-expression modification.
13. The polypeptide of claim 12 , wherein the modification comprises glycosylation, sialyation, acetylation, and/or phosphorylation.
14. The polypeptide of claim 1 , comprising an amino acid sequence at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31.
15. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13.
16. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 14.
17. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 15.
18. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 16.
19. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 17.
20. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 18.
21. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 19.
22. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 20.
23. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 21.
24. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 28.
25. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 29.
26. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 30.
27. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to SEQ ID NO: 31.
28. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
29. A pharmaceutical composition comprising the polypeptide of claim 4 and a pharmaceutically acceptable carrier.
30. The pharmaceutical composition of claim 29 , wherein the pharmaceutical composition is in solid form.
31. The pharmaceutical composition of claim 29 , wherein the pharmaceutical composition is in liquid form.
32. A pharmaceutical composition comprising the polypeptide of claim 9 and a pharmaceutically acceptable carrier.
33. The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition is in solid form.
34. The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition is in liquid form.